Avidity Biosciences, Inc.’s Post

We look forward to presenting preclinical research for our tRNA synthetase candidate ATYR0101 at the Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution. The findings presented in two posters demonstrate that ATYR0101 interacts with LTBP-1 to induce myofibroblast apoptosis through a novel anti-fibrotic mechanism to reduce fibrosis and fibrotic markers in models of lung and kidney fibrosis. The posters will be available on the aTyr website once presented. For more information, read here: https://bit.ly/41jQwpI

I am excited to share that my newest article, titled "Recent Advances in TGF-β Signaling Pathway in COVID-19 Pathogenesis: A Review," has been published in Microbial Pathogenesis. In this comprehensive review, we dive into the crucial role of TGF-β signaling in the progression of COVID-19, analyzing the latest research on its implications. We highlight various pharmacological approaches, such as nintedanib, pirfenidone, corticosteroids, proton pump inhibitors, and histone deacetylase inhibitors, that may influence the TGF-β pathway and enhance COVID-19 treatment outcomes. Moreover, we shed light on promising ongoing clinical trials focusing on mesenchymal stem cells, low-dose radiation therapy, and artemisinin derivatives, evaluating their effects on TGF-β levels and patient recovery. Access Link: https://lnkd.in/dSwwTGwE.

My latest research paper is out now on Eur J Med Chem! Bombesin tagged along for my whole PhD journey: this time we decided to conjugate some analogues to the tubulin inhibitor MMAE, to generate PDCs targeting tumours overexpressing the BB2 receptor. After some tailoring and linker optimisation, we obtained conjugates with a significant antitumour activity in mice! A huge thank you to all the co-authors for their dedication and support. (I did my best to avoid the typical LinkedIn caption, but I promise 𝘐’𝘮 𝘵𝘩𝘳𝘪𝘭𝘭𝘦𝘥 🧪✨ too) #research #targetedtherapy #peptidedrugconjugates #bombesin #phd

Johnson & Johnson is considering acquiring Intra-Cellular Therapies, a $10-billion neuroscience biotech. The potential deal could strengthen J&J's neuroscience portfolio, especially as it faces patent expirations on its immunology drug Stelara. Read the most important news of the day: longandshort.com #johnsonandjohnson #mergersandacquisitions #longandshort

ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. When motor neurons die, the brain can no longer govern voluntary movements and muscle control. Coya Therapeutics is developing COYA 302 to potentially enhance the function of regulatory T cells, also called Tregs, to target #neurodegenerative diseases like ALS. Learn more about understanding ALS from the The ALS Association here: https://lnkd.in/gHpUveK #CoyaTherapeutics #EndALS #Research

ACGT Research Fellows Nabil Ahmed, MD, and Meenakshi Hegde, MD (both of Baylor College of Medicine) led a phase 1 clinical trial using CAR T-cell therapy for advanced sarcoma. Drs. Ahmed and Hegde's CAR T cells target the HER2 protein, which is overexpressed on the surface of sarcoma cells. The HEROS 2.0 trial showed that this therapeutic approach is safe and associated with clinical benefit. One patient is cancer-free more than five years after treatment. Read more about the study: https://lnkd.in/d-V2G464

I’m attending the Muscle Stem Cells in Development, Regeneration & Adaptations Conference this week. Drop by poster #36 tonight to learn about our work using a 3D-Engineered Skeletal Muscle Organoid System to Assess Exon Skipping, Dystrophin Protein Restoration, and Functional Improvement in Human DMD Cell Models. #raredisease #duchennemusculardystrophy #societyformusclebiology

Hello guys, check out my first author original article in Scientific Reports! 💪 Highlights of the paper! -We have very nicely described a novel subtype of hepatic stellate cells ( zone 1-HSC) -This subtype of HSC resides in Zone 1 of the liver lobule under healthy conditions and loses zonation during fibrosis -Importantly, zone 1-HSC do not transform into αSMA-expressing myofibroblasts -Rather, they participate in sinusoidal capillarization in preclinical models of liver fibrosis

New Discovery in ALS Therapy! We are excited to share pivotal preclinical data on NUZ-001, marking a crucial step in our journey to transform ALS treatment.    Highlights of Preclinical Findings: 💡 NUZ-001 and its active metabolite reduced TDP-43 protein aggregation, a hallmark feature of ALS pathology. 💡Treatment improved electrophysiological dysfunction of TDP-43 mutated M337V Motor Neurons. 💡 These results provide valuable insights into NUZ-001’s mechanism of action and reinforce the promising efficacy data seen in our Phase 1 MEND study earlier this year   This discovery solidifies our path forward as we prepare with confidence for the HEALEY ALS Platform Trial. We are one step closer to providing new hope for the ALS community.   👉 Learn more in the full press release at https://lnkd.in/eCyew6pv

Pathogenic IgA in MS